Titan Medical announces the appointment of Eric Heinz as Vice President of Markets and Corporate Development for The Canadian Business Journal.

TORONTO, ON, September 26, 2022 (GLOBE NEWSWIRE) — Titan Medical Inc. (Nasdaq): TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single-access, robotic-assisted surgery (RAS), today announced Eric Heinz as the company’s market and Announced appointment as Vice President of Corporate Development. Mr. Heinz will be responsible for developing and executing a strategic business plan to expand and accelerate his cadence of Titan’s Enos™ robotic single-access surgical system portfolio. He will also aim to lead existing partnerships and complement them to maximize Titan’s reach and utilization of the Enos system. Mr. Heinz engages and collaborates with stakeholders to refine the company’s value proposition, branding, product positioning and core message.

“Eric brings a proven track record of leading initiatives to grow businesses and expand markets in the dynamic surgical robotics industry. President and CEO of Titan. said Cary Vance,

Mr. Heinz has over 20 years of medical device experience in business strategy, corporate development, product development and marketing for companies of all sizes, from small businesses to multinational corporations. He most recently served as Director of Business Development (M&A) at Smith & Nephew, leading the team responsible for executing inorganic growth strategies through M&A, equity investments and co-development partnerships. Prior to joining Smith & Nephew, Mr. Heinz consulted with his ZimmerBiomet, Medtech Surgical SA and boutique investment banks, managing quality restoration, market development and private placement projects respectively. He also worked at IMRIS where he was senior marketing manager for the SYMBIS Surgical System MRI-enabled neurosurgery robotics business, and at Intuitive Surgical where he had a $500 million instrument, accessory, and video system product in his portfolio. acted as a manager. Mr. Heinz holds a master’s degree in engineering management from Christian Brothers University and a bachelor of science degree in bioengineering from the University of Illinois at Urbana-Hie Champaign. December 2022.

About Titan Medical

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD) is a medical device company headquartered in Toronto, Ontario with operations in Chapel Hill, North Carolina that uses innovative technology through a single access point. focus on enhancing robotic-assisted surgery. The Enos™ Robotic Single Access Surgical System has been developed with a focus on ergonomics, providing a surgical experience that mimics the real-world movements demanded by the surgeon, allowing the surgeon to extend range of motion in confined spaces. It features an articulated instrument designed for Dexterity and the ability to exert force necessary to complete common surgical tasks. With the Enos system, Titan will initially pursue indications for gynecologic surgery.

Enos™ is a trademark of Titan Medical Inc.

For more information, please visit www.titanmedicalinc.com and follow us. @Titan Medical on Twitter and LinkedIn.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of applicable Canadian and US securities laws. It reflects management’s current expectations of the company’s future growth, operating results, performance and business prospects and opportunities. Whenever possible, “could”, “would”, “could”, “would”, “predict”, “believe”, “plan”, “expect”, “intend” Words such as “”, “estimate”, “may” and similar expressions are used to identify these forward-looking statements. The Enos system provides a surgical experience that mimics real-life motion. And the company’s intention to pursue gynecological surgical indications, initially with the Enos system. These statements reflect management’s current beliefs and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors may cause the actual results, performance or achievements of the Company to be expressed or implied by forward-looking statements, including but not limited to those set forth in “Risk Factors.” Future results, performance or achievements may differ materially. Section of the Company’s Annual Report for the fiscal year ended December 31, 2021. If one or more of these risks or uncertainties materializes or the assumptions underlying the forward-looking statements prove incorrect, the actual results, performance or achievements of this news release may differ. may differ materially from those expressed or implied by the forward-looking statements contained herein. These factors should be considered carefully and prospective investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in news releases are based on what management currently believes to be reasonable assumptions, but actual results, performance or achievements may differ from those forward-looking statements. We cannot guarantee that future investors will agree. Except as required by law, we do not update or revise any forward-looking statements as a result of new information, future events or otherwise. expressly disclaims any intention or obligation to

contact
Kristen Galfetti
Vice President, Investor Relations & Corporate Communications
+1-781-869-2553
[email protected]

###

CBJ Newsmaker